Skip over navigation
PEPTIDES ( peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D 519/02 ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G 69/00 ; macromolecular products derived from proteins C08H 1/00 ; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N 15/00 ; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N 33/00)
Relationship between large subject matter areas

An amino acid per se is classified in C07D while peptides (starting from dipeptides) are classified in C07K.

Subclass C07K is a function oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries in EC exist, for example: preservation of bodies of humans or animals or plants or parts thereof; Biocides, e.g. as disinfectants, as pesticides, as herbicides; pest repellants or attractants; plant growth regulators are classified in A01N.

Preparations for medical, dental, or toilet purposes are classified in A61K.

Amino acids or derivatives thereof are classified in C07C or C07D.

Multiple classification: Biocidal, pest attractant, or plant growth regulatory activity of chemical compounds or preparations is classified in A01P.

Uses of cosmetics or similar toilet preparations are further classified in A61Q.

References relevant to classification in this subclass
This subclass/group does not cover:
Peptides containing beta-lactam rings
Cyclic dipeptides not having in their molecule any other peptide link than those which form their ring; e.g. piperazine-2,5-diones
Ergot alkaloids of the cyclic peptide type
Enzymes
Genetic engineering processes for obtaining peptides
Peptides and proteins obtained by fermentation or enzyme-using processes are classified in
Electrolytic production of organic compounds
Informative references
Attention is drawn to the following places, which may be of interest for search:
Peptides in foodstuffs
Peptides in animal feed
MacromoIecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific, but for a random sequence of the amino acid units, homopolyamides and block copolyamids derived from amino acids
Macromolecular products derived from proteins
Preparation of glue or gelatine
Micro-organisms
Compositions for measuring or testing processes involving enzymes
Investigation or analysis of biological materials
Analytical devices
Special rules of classification within this group

In this subclass, in the absence of an indication to the contrary, a compound is classified in the last appropriate place.

Fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the parent peptides (however only if they have the same activity). Peptide fragments having up to four amino acids are classified in group C07K 5/00.

Peptides prepared by chemical processes or having an amino acid sequence derived from naturally occurring peptides are classified with the naturally occurring peptide.

Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.

When classifying in this subclass, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.

Specific peptides mentioned in the claims and/or examples are classified.

The technical field of C07K 1/00 to C07K 5/126 is subdivided into three major blocks:

General methods for preparation of peptides/proteins
General methods for extraction, separation and purification of proteins and peptides
Peptide compounds per se containing up to four amino acids
Should not be used anymore for classification
Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Amino acid
compounds in which at least one amino acid group and at least one carboxylic group are bound to the same carbon skeleton and the nitrogen atom of the amino group may be part of a ring
Normal peptide link
a link between an alpha-amino group of an amino acid and the carboxylic group in position 1 of another alpha-amino acid
Abnormal peptide link
a link where at least one of the linked amino acids is not an alpha- amino acid or a link formed by at least one carboxyl or amino group being a part of the side chain of an alpha-amino acid. Peptide compounds containing at least two amino acid units, which are bound through at least one normal peptide link, including oligopeptides, polypeptides and proteins.
Linear peptides
may comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy- or a mercapto-amino acid and the carboxyl group of another amino acid (e.g. peptide lactones) but do not comprise rings which are formed only through peptide links.
Cyclic peptides
comprising at least one ring formed only through peptide links; the cyclisation may occur only through normal peptide links or through abnormal peptide links, e.g. through the 4-amino group of 2,4-diamino-butanoic acid. Thus, cyclic compounds in which at least one link in the ring is a non-peptide link are considered as' linear peptides'.
Depsipeptides
compounds containing a sequence of at least two alpha-amino acids and at least one alpha-hydroxy carboxylic acid, which are bound through at least one normal peptide link and ester link, derived from the hydroxy carboxylic acids
Linear depsipeptides
may comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy- or mercapto-amino and and the carboxyl group of another amino- or hydroxy-acid but do not comprise rings formed only through peptide or ester links derived from hydroxy carboxylic acids, e.g. Gly-Ala-Gly-OCH2CO2H and Gly-OCH2CO-Ala-Gly are considered as “linear depsipeptides, but HOCH2CO-Gly-Ala-Gly does not contain an ester link, and is thus a derivative of Gly-Ala-Gly which is covered by C07K 5/08
Cyclic depsipeptides
are peptides containing at least one ring formed only through peptide or ester link - derived from hydroxy carboxylic acids -, e.g. Gly-Ala-Gly-OCH2CO
Hybrid peptides
are peptides produced through fusion or covalent binding of two or more heterologous peptides.
General methods for the preparation of peptides {i.e. processes for the organic chemical preparation of peptides or proteins of any length}
Definition statement
This subclass/group covers:

General processes for the organic chemical preparation of peptides (exception see C07K 1/113).

Peptides e.g. oligopeptides, polypeptides, proteins Immunoglobulins.

Carrier-bound or immobilised peptides and preparation thereof.

Hybridpeptides.

"Peptides" in this main group includes oligopeptides, polypeptides, proteins and chemically modified forms thereof, i.e. the definition of peptide is independent of the length in amino acids.

Peptides comprise at least two alpha-amino acids joined by a single peptide bond.

{by transforming the C-terminal amino acid to amides}
Definition statement
This subclass/group covers:

Reactions concerning transformation of the C-terminal amino acid to amides.

{of peptides containing derivatised side chain amino acids}
Definition statement
This subclass/group covers:

Preparation of peptides containing derivatised side chain amino acids such as e.g. pseudo proline, non natural amino acids, and chemically phosphorylated amino acids.

in solution { (C07K 1/003 , C07K 1/006 take precedence ) }
Definition statement
This subclass/group covers:

General methods for solution phase peptide synthesis.

Special rules of classification within this group

Main group concerns methods for solution phase peptide synthesis applicable to peptides in general. Methods directed to solution phase peptide synthesis of a single peptide or protein needs to be classified in the pertinent group for that specific peptide or protein.

C07K 1/003, C07K 1/006 take precedence.

The class C07K 1/023 should be given if the focus of solution phase peptide synthesis is on inhibition of racemate formation.

Solution-phase peptide synthesis may comprise enzymes as catalysts.

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Peptides
oligopeptides, polypeptides, proteins and chemically modified forms thereof.
on carriers { (C07K 1/003 , C07K 1/006 take precedence ) }
Special rules of classification within this group

C07K 1/003, C07K 1/006 take precedence.

Specific aspects of synthesis on carriers, such as deprotection, new solvents, should be classified in the respective subclasses.

{using devices to improve synthesis, e.g. reactors, special vessels}
References relevant to classification in this group
This subclass/group does not cover:
Apparatus per se
{Simultaneous synthesis of different peptide species; Peptide libraries}
Definition statement
This subclass/group covers:

Organic chemical methods for simultaneous multiple peptide synthesis and organic chemical synthesis of peptide libraries.

References relevant to classification in this group
This subclass/group does not cover:
Combinatorial chemical libraries
C07B61/00L
Carrier-bound immobilised peptides are classified in, if the invention relies in the carrier and/or the anchoring linkages
Libraries per se, arrays, containing peptides or polypeptides, or derivatives thereof
Peptide libraries produced by recombinant DNA technology
using protecting groups or activating agents { (C07K 1/003 , C07K 1/006 take precedence ) }
Definition statement
This subclass/group covers:

General methods for the preparation of peptides using protecting groups or activating agents.

Special rules of classification within this group

Multiple classification if a plurality of protecting groups is claimed.

Please avoid, where possible, classification in the head group C07K/06,

C07K 1/003, C07K 1/006 take precedence.

using activating agents { (C07K 1/003 , C07K 1/006 take precedence ) }
Special rules of classification within this group

C07K 1/003, C07K 1/006 take precedence.

For coupling of peptides the carboxyl group is activated. Thus activating agent are generally agents which activate the carboxyl group by forming an activated ester, such as DCC, DIC, BOP, PyBOP, HBTU, TBTU.

Activating agents are to be distiguished from coupling agents which do not form an activated ester but are oxidized during the peptide bond formation.

using coupling agents { (C07K 1/006 takes precedence ) }
Definition statement
This subclass/group covers:

General methods for the preparation of peptides using coupling agents.

Special rules of classification within this group

C07K 1/006 takes precedence.

For coupling of peptides the carboxyl group is activated. Thus activating agent are generally agents which activate the carboxyl group by forming an activated ester, such as DCC, DIC, BOP, PyBOP, HBTU, TBTU.

Activating agents are to be distinguished from coupling agents which do not form an activated ester but are oxidized during the peptide bond formation.

{by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
Definition statement
This subclass/group covers:

General methods for the preparation of peptides by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids.

References relevant to classification in this group
This subclass/group does not cover:
Combinatorial chemical libraries
C07B61/00L
Carrier-bound immobilised peptides
Libraries per se, arrays, containing peptides or polypeptides, or derivatives thereof
Peptide libraries produced by recombinant DNA technology
Special rules of classification within this group

Peptide arrays or libraries are NOT classified in C07K 1/1077.

without change of the primary structure
Definition statement
This subclass/group covers:

General methods for the preparation of peptides without change in the primary structure, e.g. by reversible modification of the secondary, tertiary or quaternary structure.

Special rules of classification within this group

In this subclass as an exception to the general rule that methods have to be applicable to peptides in general, exceptionally also methods relating to a single peptide or protein are classified.

by hydrolysis {i.e. solvolysis in general}
References relevant to classification in this group
This subclass/group does not cover:
Peptides obtained by fermentation
Special rules of classification within this group

Documents directed to peptide or protein sequencing have also been classified in the past in G01N 33/68.

General methods for the preparation of peptides by hydrolysis covers peptide or protein sequencing techniques (sequential hydrolysis of peptides or protein).

Labelling of peptides
Definition statement
This subclass/group covers:

General chemical methods for the preparation of peptides by labelling e.g. with dyes, radioactive or fluorescents labels.

Subgroup concerns methods which are applicable to peptides of any length in general! Methods directed to the preparation of a specific peptide or protein needs to be classified in the pertinent group for that specific peptide or protein.

Relationship between large subject matter areas

Isotope labelled peptides per se are classified in C07B 59/008.

Informative references
Attention is drawn to the following places, which may be of interest for search:
Peptides forming the non active part of a conjugate for use as a therapeutic agent
Peptides forming the non active part of a conjugate for use as an in vivo imaging agent by fluorescense
Peptides possibly part of a conjugate, for use as an in vivo imaging agent by X-ray imaging
Peptides possibly part of a conjugate for use as an in vivo imaging agent by magnetic resonance imaging
Peptides possibly part of a conjugate for use as an in vivo imaging agent by ultrasound imaging
Preparations containing radioactive peptides for use in therapy and in vivo imaging are classified in Preparations containing radioactive peptides for use in therapy and in vivo imaging
Peptide conjugates where the innovation is on the conjugated part
Extraction; Separation; Purification
References relevant to classification in this group
This subclass/group does not cover:

Methods directed to purification of antibodies from serum, plasma, or other body fluids are classified in C07K 16/065. However, if the focus is on technical aspect of purification as such, the method should also be classified in C07K 1/14 - C07K 1/36. Purification of antibodies from a solution, cell culture, and the like, is classified in C07K 1/14 - C07K 1/36.

Informative references
Attention is drawn to the following places, which may be of interest for search:
Antibodies isolated from milk are also classified in
Special rules of classification within this group

Please avoid where you can classifying in the head group.

by chromatography
Definition statement
This subclass/group covers:

Only chromatographic methods applicable for peptides or proteins as such are classified here.

Relationship between large subject matter areas

Chromatographic materials as such are classified in B01J 20/281 - B01J 20/292, B01J 39/26 (cation exchangers), B01J 41/20 (anion exchangers).

B01D 15/08 relates to processes and apparatus for chromatography in general.

{by crystallization}
References relevant to classification in this group
This subclass/group does not cover:
Methods with emphasis on growing large single crystals of protein from solutions
For the crystal
by a combination of two or more processes of different types
Definition statement
This subclass/group covers:

A combination of two or more processes of different types means that at least two steps are innovative.

Peptides of undefined number of amino acids; Derivatives thereof
Special rules of classification within this group

Please avoid classifying in this group. Consider classification only in exceptional cases where the protein is not identifiable by the sequence or otherwise.

Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
Special rules of classification within this group

Please avoid classifying in this group. Consider classification only in exceptional cases where the protein is not identifiable by the sequence or otherwise.

Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
Definition statement
This subclass/group covers:

Peptides containing up to four amino acids in a fully defined sequence and derivatives thereof. Peptides containing up to four amino acids in a fully defined sequence and containing saccharide radicals are not covered by this group (see references relevant to classification below).

References relevant to classification in this group
This subclass/group does not cover:
Medical uses of novel short peptides
Dipeptides
Tripeptides
Tetrapeptides
Depsipeptides
Cosmetic preparations containing peptides
Peptides containing up to four amino acids in a fully defined sequence and containing saccharide radicals
Informative references
Attention is drawn to the following places, which may be of interest for search:
Peptides with up to 4 amino acids labelled with isotopes are also classified in
Depsipeptides with up to 4 amino acids are also classified in
Peptides with up to four amino acids prepared by fermentation (not recombinantly expressed) are also classified in
Chemically synthesized hybrid peptides with up to 4 amino acids are also classified in
Fusion polypeptides
Peptides up to 4 amino acids in length forming the non active part of a conjugate, for use as a therapeutic agent, are also classified in
Peptides up to 4 amino acids in length forming the active part of a conjugate to an antibody, for use as a therapeutic agent, are also classified in
Peptides up to 4 amino acids in length forming the non active part of a conjugate, for use as an in vivo imaging agent by fluorescense, are also classified in
Peptides up to 4 amino acids in length, possibly part of a conjugate, for use as an in vivo imaging agent by X-ray imaging, are also classified in
Peptides up to 4 amino acids in length, possibly part of a conjugate, for use as an in vivo imaging agent by magnetic resonance imaging, are also classified in
Peptides up to 4 amino acids in length, possibly part of a conjugate, for use as an in vivo imaging agent by ultrasound imaging, are also classified in
Preparations containing radioactive peptides for use in therapy and in vivo imaging are also classified in
Peptide conjugates where the innovation is on the conjugated part are classified in
Special rules of classification within this group

Although C07K 5/00- C07K 5/126 concern short peptides per se, there is one exception: methods for purification and preparation of aspartame are classified with aspartame in C07K 5/0613.

containing at least one abnormal peptide link
Definition statement
This subclass/group covers:

Peptides per se, and derivatives thereof, having up to four amino acids in a fully defined sequence and containing at least one abnormal peptide link are classified in this subgroup only.

Special rules of classification within this group

Mainly protease inhibitors, such as statins, have been classified here.

{containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-}
Definition statement
This subclass/group covers:

Peptides, and derivatives thereof, having up to four amino acids in a fully defined sequence and containing the structure [-C(=O)-C-N-C(=O)-N-C-C(=O)-]

Special rules of classification within this group

Peptides with symmetrical structure.

containing only normal peptide links
Definition statement
This subclass/group covers:

Peptides, and derivatives thereof, having up to four amino acids in a fully defined sequence and containing only normal peptide links.

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Neutral amino acids
have in their side chains the same number of amino groups and carboxylic acid groups or derivatives thereof, e.g. Gly
Basic amino acids
have in their side chains more amino groups than carboxylic acid groups or derivatives thereof, e.g. Arg, Lys
Acidic amino acids
have in their side chains more carboxylic acid groups or derivatives thereof than amino groups, e.g. Asp, Glu; Gln and Asn are also considered as acidic amino acids
Aliphatic amino acids
have only acyclic carbon atoms in their side chains, e.g. Ala
Aromatic or cycloaliphatic amino acids
have a carbocyclic in ring in their side chains, e.g. Phe
Heterocyclic amino acids
are amino acids wherein the side chain contains or is part of a heteroring, e.g. Pro, His, Trp
Side chain
the R radical in the optionally functionalised amino acid RCH(NH2)C O2H)
First amino acid
means the N-terminal amino acid of the peptide sequence
{Aspartame}
Special rules of classification within this group

Although C07K 5/00- C07K 5/126 concern short peptides per se, there is one exception: methods for purification and preparation of aspartame are classified with aspartame in C07K 5/0613.

Cyclic peptides {with only normal peptide bonds in the ring}
Definition statement
This subclass/group covers:

Peptides, and derivatives thereof, having up to four amino acids in a fully defined sequence in a cyclic form and containing only normal peptide bonds.

References relevant to classification in this group
This subclass/group does not cover:
Cyclic peptides containing at least one abnormal peptide link
Special rules of classification within this group

Classify here only if cyclisation occurs via normal peptide links.

Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Definition statement
This subclass/group covers:
  • Oligomers of amino acids making up a sequence of between 5 and 20 residues in length containing at least one alpha peptide bond, which is also a normal peptide bond.
  • Genes and nucleotide sequences coding for the above peptides.
  • Crystals of the above peptides.
  • Specific methods for the preparation of the above peptides.

Peptides having 5 to 20 amino acids in a fully defined sequence and containing saccharide radicals are not covered by this group (see references relevant to classification below).

References relevant to classification in this group
This subclass/group does not cover:
Pharmaceutical/dental/cosmetic/toilet uses and compositions of peptides that were already known at the time are classified in
E.g. in one or more of the following:For dental, cosmetic and toilet indications:
For pharmaceutical and medical purposes
Fragments of proteins should be classified with the parent polypeptide
Fragments of enzymes should be classified with the parent compound
Fragments of immunoglobulins should be classified with the parent compound
Fragments of peptides included in this main group and having 4 or less amino acids
Peptides having 5 to 20 amino acids in a fully defined sequence and containing saccharide radicals
Peptides in foodstuff
Investigation or analysis of peptides, including peptide sequencing, as well as diagnostic and/or analytical uses of peptides
Methods for the preparation of generic peptides (e.g. by chemical synthesis)
Methods for the preparation of generic peptides (fermentative or enzyme-based procedures)
Oligomers of amino acids with no normal peptide bond are classified with the organic compounds in the preceding
Fusion peptides are additionally classified in
Documents in which the emphasis is laid on the method of preparation of fusion proteins may also be classified in
Special rules of classification within this group

In this main group, only the specific embodiments are classified. The generic definition of a group of peptides on the basis of structural variables, which may assume different values, e.g. a Markush formula, deserves no classification mark.

In this main group, in the absence of any indication to the contrary, every specific embodiment is classified in the last appropriate place (last-place rule).

As a consequence, one embodiment can only be associated with one classification mark within C07K. A document disclosing a plurality of specific embodiments may be associated with one or more classification marks.

Peptides modified by means of one or more of additions, deletions and substitutions of amino acids are classified as the parent peptide.

As a corollary, fragments of peptides are classified with the parent peptides, which contain their sequences.

The degree of structural homology is not particularly limited, as long as the origin of the fragment or the modified peptide is established on the basis of at least one function/activity in common with the parent peptide.

Fusion peptides are classified in the classes of their components, and additionally in C07K 2319/00.

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Amino acids
Are compounds in which at least one amino group and at least one carboxyl group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form part of a ring
Normal peptide link
Is one between an alpha-amino group of an amino acid and the alpha- carboxy group of another alpha-amino acid
Abnormal peptide link
Is a link where at least one of the linked amino acids is not an alpha-amino acid or a link formed by at least one carboxyl or amino group being part of the side chain of an alpha-amino acid
Peptides
Are compounds containing at least two amino acid units, which are bound through at least one normal peptide link, including oligopeptides, polypeptides and proteins
Linear peptides
Are normal or abnormal peptides which may comprise rings formed through S-S bridges, or through a hydroxy or a mercapto group of an hydroxy -or mercaptoamino acid and the carboxyl group of another amino acid, (e.g. peptide lactones) but do not comprise rings which are formed only through peptide links
Cyclic peptides
Are peptides comprising at least one ring formed only through peptide links; the cyclisation may occur only through normal peptide links or through abnormal peptide links, e.g. through the 4-amino group of 2,4-diamino-butanoic acid. Cyclic compounds in which at least one link in the ring is a non-peptide link are considered as "linear peptides"
Related peptide and peptide derivative
It is intended a peptide, which retains at least one function/activity of the parent peptide.
Defined sequence and undefined sequence
Are used here in order to characterize an intrinsic property of the peptide, and do not refer to the actual knowledge of the amino acid sequence, i.e. the adjective defined is not used here with the same meaning of determined. Peptides with a "defined sequence" have an unique amino acid sequence and are classified as such even if their amino acid sequence has not been disclosed and is not known. An "undefined sequence" means a degeneration of the sequence information, e.g. if the peptide is defined as a random sequence of various amino acids.
Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
Definition statement
This subclass/group covers:

Peptides having up to 20 amino acids containing saccharide radicals and having a fully defined sequence and derivatives thereof. They must have at least one normal peptide link. The peptides classified above are often called glycopeptides and are defined as peptides of appropriate length (see C07K 7/00) possessing one or more glycoside groups on the side chain(s) of the constituting peptides.

Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Definition statement
This subclass/group covers:

Depsipeptides having up to 20 amino acids in a fully defined sequence. Derivatives thereof.

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Depsipeptides
are compounds containing a sequence of at least two alpha-amino acids and at least one alpha-hydroxy carboxylic acid, which are bound through at least one normal peptide link and at least an ester link, derived from the hydroxy carboxylic acid.
Linear depsipeptides
may comprise rings formed through S-S bridges, or through an hydroxy or a mercapto group of an hydroxy-or mercapto-amino acid and the carboxyl group of another amino- of hydroxy-acid, but do not comprise rings formed only through peptide or ester links derived from alpha-hydroxy carboxylic acids; e.g. Gly-Ala-Gly-OCH2CO2H and Gly-OCH2CO-Ala-Gly are considered as "linear depsipeptides", but HOCH2CO-Gly-Ala-Gly does not contain an ester link, and is thus a derivative of Gly-Ala- Gly which is covered by C07K 5/08.
Cyclic depsipeptides
are peptides containing at least one ring formed only through peptide or ester links derived from alpha-hydroxy carboxylic acids,e.g. cyclic Gly-Ala-Gly-OCH2CO.
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Definition statement
This subclass/group covers:
  • Polymers of amino acids linked by peptide bonds, and compositions containing them.
  • Genes and other polynucleotides coding for peptides.
  • Non-coding nucleic acid sequences, e.g. promoters, operators, derived from genes or operons coding for peptides
  • Fragments of peptides and nucleic acids encoding peptides (fragments smaller than 21 amino acids are classified with the parent peptides; fragments of 2-4 amino acid residues are also classified in C07K 5/00
  • Methods for preparation and purification of specific peptides are classified with these peptides. General methods are classified in C07K 1/00.
  • Fusion proteins
  • Crystallized proteins
  • Hybrid peptides (classified according to their peptide component)
Relationship between large subject matter areas

Medicinal preparations containing known peptides are not classified in C07K, only in A61K.

References relevant to classification in this group
This subclass/group does not cover:
Enzymes
Immunoglobulins
Peptides having less than 21 amino acids
Carrier-bound or immobilised peptides and preparation thereof
Proteins of humans and other mammals

Examples where the subject matter of this main group is covered when specially adapted, used for a particular purpose, or incorporated in a larger system:

Medicinal preparations containing peptides
Peptides with enzymatic activity
Informative references
Attention is drawn to the following places, which may be of interest for search:
Peptides in foodstuff
Compositions for measuring or testing processes involving peptides
Investigation or analysis of peptides
Special rules of classification within this group

In this subclass, in the absence of an indication to the contrary, a compound is classified in the last appropriate place.

Methods for the preparation or purification of specific peptides are classified in the group of the corresponding peptides. However, the invention may also be valid for other peptides and such documents are also classified in C07K 1/00.

Fragments of peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the parent peptides. However, fragments of peptides having four or less amino acids are also classified in group C07K 5/00.

Specific peptides prepared by chemical processes or peptides having an amino acid sequence derived from specific peptides are classified with the specific peptides.

Protease inhibitors that are fragments of proteases are classified only in C12N 9/50-C12N 9/86, not in C07K 14/81.

Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.

Fusion peptides are classified in the classes of their components, the document has further to be given a class for fusion proteins: C07K 2319/00

Documents in which emphasis is given on the method for the preparation of fusion proteins are classified in C12N 15/62.

Hybrid peptides are classified according to their peptide component.

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Amino acid
compounds in which at least one amine and at least one carboxylic group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form a ring
Peptide bond
a link between an alpha-amino group of an amino acid and the carboxylic group – in position 1 – of another alpha-amino acid
Immunoglobulin
protein produced by B cells, made up of two identical heavy and two identical light chains, held together by interchain disulfide bonds
Hybrid peptide
peptide comprising components of heterologous molecules
Fusion peptide
peptide consisting of (parts of) different proteins covalently linked to each other by a peptide bond
Signal sequence
a 3-60 amino acids stretch that directs the transport of the protein to which it is attached
{by chemical synthesis}
Definition statement
This subclass/group covers:

Preparation of proteins and peptides having more than 20 amino acids, and derivatives thereof, by chemical synthesis.

{Peptide-nucleic acids (PNAs)}
Definition statement
This subclass/group covers:

Chemical synthesis of peptide-nucleic acids in which the peptide contains more than 20 amino acids.

from viruses
Definition statement
This subclass/group covers:

New viral proteins or individual genes encoding said proteins, as well as new structural or functional aspects of known viral proteins or genes. Also fragments of said proteins or genes are covered.

Special rules of classification within this group

The subdivision corresponding to IPC C07K 14/01 until C07K 14/19 is no longer used, since the taxonomic division in this part of the IPC is incomplete and inconsistent with other parts of the classification relating to viruses.

The viral proteins, genes and fragments as indicated above are to be classified using the codes in the C12N 2710/00-C12N 2795/00 ranges combining taxonomic information with further aspects, whereby the specific ending 22 relates to aspects of individual viral proteins and their corresponding genes.

Only if the main invention resides in the viral protein, individual gene or fragment thereof, C07K 14/005 is to be given. No other EC class should be assigned.

from animals; from humans
Definition statement
This subclass/group covers:
  • Polymers of amino acids linked by peptide bonds, and compositions containing them.
  • Genes and other polynucleotides coding for peptides.
  • Non-coding nucleic acid sequences, e.g. promoters, operators, derived from genes or operons coding for peptides
  • Fragments of peptides and nucleic acids encoding peptides (fragments smaller than 21 amino acids are classified with the parent peptides; fragments of 2-4 amino acid residues are also classified in C07K 5/00
  • Methods for preparation and purification of specific peptides are classified with these peptides. General methods are classified in C07K 1/00.
  • Fusion proteins
  • Crystallized proteins
  • Hybrid peptides (classified according to their peptide component)
Relationship between large subject matter areas

Medicinal preparations containing known peptides are not classified in C07K, only in A61K.

References relevant to classification in this group
This subclass/group does not cover:
Enzymes
Immunoglobulins
Peptides having less than 21 amino acids
Carrier-bound or immobilised peptides and preparation thereof
Proteins of humans and other mammals

Examples where the subject matter of this main group is covered when specially adapted, used for a particular purpose, or incorporated in a larger system:

Medicinal preparations containing peptides
Peptides with enzymatic activity
Informative references
Attention is drawn to the following places, which may be of interest for search:
Peptides in foodstuff
Compositions for measuring or testing processes involving peptides
Investigation or analysis of peptides
Special rules of classification within this group

In this subclass, in the absence of an indication to the contrary, a compound is classified in the last appropriate place.

Methods for the preparation or purification of specific peptides are classified in the group of the corresponding peptides. However, the invention may also be valid for other peptides and such documents are also classified in C07K 1/00.

Fragments of peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the parent peptides. However, fragments of peptides having four or less amino acids are also classified in group C07K 5/00.

Specific peptides prepared by chemical processes or peptides having an amino acid sequence derived from specific peptides are classified with the specific peptides.

Protease inhibitors that are fragments of proteases are classified only in C12N 9/50-C12N 9/86, not in C07K 14/81.

Peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. HIV peptide expressed in E. coli is classified with HIV peptides.

Fusion peptides are classified in the classes of their components, the document has further to be given a class for fusion proteins: C07K 2319/00

Documents in which emphasis is given on the method for the preparation of fusion proteins are classified in C12N 15/62.

Hybrid peptides are classified according to their peptide component.

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Amino acid
compounds in which at least one amine and at least one carboxylic group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form a ring
Peptide bond
a link between an alpha-amino group of an amino acid and the carboxylic group – in position 1 – of another alpha-amino acid
Immunoglobulin
protein produced by B cells, made up of two identical heavy and two identical light chains, held together by interchain disulfide bonds
Hybrid peptide
peptide comprising components of heterologous molecules
Fusion peptide
peptide consisting of (parts of) different proteins covalently linked to each other by a peptide bond
Signal sequence
a 3-60 amino acids stretch that directs the transport of the protein to which it is attached
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies { ( antibodies with enzymatic activity, e.g. abzymes C12N 9/0002) }
Definition statement
This subclass/group covers:
  • Antibodies, immunoglobulins and proteins derived therefrom that bind a specific antigen, and have as minimal structural features an immunoglobulin framework and three CDRs (i.e. a variable domain). In addition, antibody mimetics and scaffolds that bind a specific antigen. The terms antibodies and immunoglobulins are often used interchangeably.
  • This maingroup covers the following aspects of antibodies:

Structure

Production

Specificity

Cells producing the antibody, e.g. hybridomas producing a monoclonal antibody

DNA/RNA encoding an antibody

  • Therapeutic and prophylactic use
  • Diagnostic use and use for detection
  • Fusion proteins comprising at least the antigen-binding region of an antibody

Antibody mimetics and scaffolds.

References relevant to classification in this group
This subclass/group does not cover:
Antibody with enzymatic /catalytic activity, e.g. abzymes
Stabilization of antibody compositions, e.g. for storage or administration
Fusion protein of an Fc-region of an immunoglobulin + a non-antibody protein

Examples of places where the subject matter of this maingroup is covered when specially adapted, used for a particular purpose, or incorporated in a larger system:

Medicinal preparations containing blood products
Medicinal preparations containing peptides
Mixtures of active ingredients without chemical characterization
Stabilization of medicinal preparations comprising antibodies
Medicinal preparations comprising a mixture of an antibody and a non-antibody
Medicinal preparations comprising immunoconjugates
Gene therapy
Antibodies containing fluorescent labels for use in detection in vivo
Antibodies containing NMR labels for use in detection in vivo
Antibodies containing radioactive substances for use in therapy or detection in vivo
Antibodies with enzymatic activity
Immunoassay; biospecific binding assay
Informative references
Attention is drawn to the following places, which may be of interest for search:
Stabilization of medicinal preparations comprising antibodies
Medicinal preparations comprising a mixture of an antibody and a non-antibody
Medicinal preparations comprising immunoconjugates
Antibodies containing fluorescent labels for use in detection in vivo
Antibodies containing NMR labels for use in detection in vivo
Antibodies containing radioactive substances for use in therapy or detection in vivo
General methods for the preparation of peptides
Peptides having more than 20 amino acids
Antibodies with enzymatic activity
Immunoassay; biospecific binding assay
Special rules of classification within this group

At least one group is mandatory, Indexing Code are to be used only for relevant and sufficiently disclosed aspects, e.g. aspects actually disclosed in examples, not just casually claimed or generally referred to in the description

New antibody and/or fragments or derivatives thereof, i.e. the product per se. Emphasis is on the antigen specificity of the antibody.

C07K 16/00 (classified according to specificity *), see the following examples:

C07K 16/08 (against material from viruses)

C07K 16/081 or subgroups thereof (against material from DNA viruses)

C07K 16/10 or subgroups thereof (against material from RNA viruses)

C07K 16/12 or subgroups thereof (against material from bacteria)

C07K 16/14 (against material from fungi, algae or lichens)

C07K 16/16 (against material from plants)

C07K 16/18 (against material from animals or humans)

C07K 16/20 (against material from protozoa)

C07K 16/22 (against growth factors)

C07K 16/24 or subgroups thereof (against cytokines, lymphokines or interferons)

C07K 16/26 (against hormones)

C07K 16/28 or subgroups thereof (against receptors)

C07K 16/30 or subgroups thereof (against tumor antigens)

C07K 16/32 (against translation products of oncogenes)

C07K 16/34 (against blood group antigens)

C07K 16/36 (against blood coagulation factors)

C07K 16/38 (against protease inhibitors of peptide structure)

C07K 16/40 (against enzymes)

C07K 16/42 or subgroups thereof (against immunoglobulins)

C07K 16/44 (against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, individual amino acid residues, phosphorylated residues)

If an antigen that, under "normal/benign" conditions, justifies a class for the specifically binding antibody in the C07K 16/08 - C07K 16/28 and C07K 16/34-C07K 16/44 ranges *, is disclosed to be (over)expressed under malignant conditions (e.g. in or on a tumor cell), then an additional antibody class in the C07K 16/30 - C07K 16/32 (i.e. antibodies against tumor, resp. oncogene antigens) ranges should be given.

Antibody or fragments or derivatives thereof. Emphasis is on a new technique of the construction of the immunoglobulin molecule or derivative thereof.

C07K 16/00 (general) or C07K 16/005 (phage display)

optionally C07K 16/00(for the specificity *, if in an example)

DNA/RNA encoding an antibody or a fragment thereof.

C07K 16/00(for the specificity *)

No Indexing Code used for the aspect of DNA/RNA.

Hybridoma producing a monoclonal antibody. Emphasis is on the antigen specificity of the monoclonal antibody.

C07K 16/00(for the specificity *)

No Indexing Code used for aspect of hybridoma.

Hybridoma producing a monoclonal antibody. Emphasis is on the technique of producing the hybridoma.

C12N 5/00(for the hybridoma cell) and/or

C12N 15/00(for the hybridoma technique)

optionally C07K 16/00(for the specificity, if there is an example *)

Fusion protein of (at least an antigen-binding part of) an antibody + a non-antibody protein. Not to be confused with ‘synthebodies’, see further below.

C07K 16/00 (for the specificity of the antibody part *)

C07K 14/00 (for the non-antibody part)

Indexing Code C07K 2319/00 (fusion protein)

Fusion protein of an Fc-region of an immunoglobulin + a non-antibody protein.

C07K 14/00 (for the non-antibody part)

Indexing Code C07K 2319/30 (Fc fused to non-Ig)

Chemical conjugate of (at least an antigen-binding part of) an antibody + a toxin or drug.

C07K 16/00 (for the specificity *) and

A61K 47/48369 or subgroups thereof (if the antibody contains a drug or toxin for use in therapy in vivo) and/or

A61K 51/10 or subgroups thereof (if the antibody contains a radioactive substance for use in therapy in vivo)

Chemical conjugate of (at least an antigen-binding part of) an antibody + a detectable label.

C07K 16/00 (for the specificity *) and

G01N 33/53 or subgroups thereof (if the antibody is for use in detection in vitro) and/or

A61K 51/10 or subgroups thereof (if the antibody contains a radioactive substance for use in detection in vivo) and/or

A61K 49/0058 (if the antibody contains a fluorescent label for use in detection in vivo) and/or

A61K 49/16 (if the antibody contains a nuclear magnetic resonance label for use in detection in vivo)

Therapeutic use of an antibody or a therapeutic composition comprising an antibody.

C07K 16/00 (for the specificity *), and

Indexing Code A61K 2039/505 (therapeutic use of an antibody, but only if in an in vivo example. Note: Because at the date of classification it is not foreseeable how plausible an in vitro assay will be for the assessment of therapeutic effectiveness, in vitro examples, including those that make in vivo therapeutic effectiveness plausible, should be classified in the C07K 2317/70 series, see below), and/or

optionally Indexing Code A61K 2039/54 (route of administration, but only if important), and/or

optionally Indexing Code A61K 2039/545 (dose, timing or administration schedule, but only if important), and/or

optionally Indexing Code A61K 2039/57 (type of response, e.g. TH1- or TH2-type T cell response).

Therapeutic use of a combination of two or more antibodies or a therapeutic composition comprising two or more antibodies. Said antibodies have an additive or synergistic effect, and the antibodies may be given as a mixture or consecutively. This should not to be confused with a mixture of an antibody with a non-antibody, see below.

ECLA class C07K 16/00 (for the specificity of the first antibody *), and

ECLA class C07K 16/00 (for the specificity of the second antibody *), and

Indexing Code A61K 2039/507 (therapeutic use of an antibody combination, but only if in an in vivo example), and/or

optionally Indexing Code A61K 2039/54 (route of administration, but only if important), and/or

optionally Indexing Code A61K 2039/545 (dose, timing or administration schedule, but only if important), and/or

optionally Indexing Code A61K 2039/57 (type of response, e.g. TH1- or TH2-type response).

Therapeutic combinations of antibodies (or fragments thereof) + non-antibody proteins, or compositions comprising these combinations.

A61K 38/00 (for the non-antibody protein)

C07K 16/00 (for the specificity *).

Therapeutic combinations of antibodies (or fragments thereof) + structurally undefined (e.g. functionally defined) compounds, or compositions comprising these combinations.

A61K 45/06 (for the structurally undefined compound)

C07K 16/00(for the specificity *).

Therapeutic combinations of antibodies (or fragments thereof) + blood-derived cells, or compositions comprising these combinations.

A61K 35/14 (for the blood-derived cells)

C07K 16/00 (for the specificity *).

Diagnostic use of an antibody, or a diagnostic composition comprising an antibody. Emphasis is on the antigen specificity, not on the assay technique.

C07K 16/00 (for the specificity *)

No Indexing Code used for aspect of diagnosis.

Diagnostic use of an antibody, or a diagnostic composition comprising an antibody. Emphasis is on a new assay technique. The antigen specificity may not be crucial.

G01N 33/53 or subgroups thereof.

C07K 16/00 (for the specificity, if there is an example *).

Antibody isolated from eggs. Emphasis is on the isolation technique, not on the antigen specificity.

C07K 16/02 (for the isolation technique from eggs), and

C07K 16/00 (for the specificity, if in an example *)

Antibody isolated from eggs. Emphasis is on the antigen specificity, not on the technique of isolation.

ECLA class C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/11 (antibody isolated from eggs)

Antibody isolated from milk. Emphasis is on the isolation technique, not on the antigen specificity.

C07K 16/04 (for the isolation technique from milk), and

optionally C07K 16/00 (for the specificity, if in an example *)

Antibody isolated from milk. Emphasis is on the antigen specificity, not on the technique of isolation.

C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/12 (antibody isolated from milk)

Antibody isolated from serum. Emphasis is on the isolation technique, not on the antigen specificity.

C07K 16/06 (for the isolation technique from serum), and

optionally C07K 16/00 (for the specificity, if in an example *)

Note: The term "serum" should be interpreted widely and includes blood and plasma as well. In practice, the subgroup C07K 16/065 is used more often and relates to the purification (e.g. by chromatography, filtration) and fragmentation (e.g. by enzymatic digestion) of the immunoglobulin.

Antibody isolated from plants. Emphasis is on the antigen specificity, not on the technique of isolation.

ECLA class C07K 16/00(for the specificity *), and

Indexing Code C07K 2317/13 (antibody isolated from plants)

Antibody characterized by their source of isolation or production. Emphasis is on the protein-expression technique, e.g. to improve yield, purity or glycosylation, e.g. by using specific host-cells, vectors, additives or culture conditions.

ECLA class C07K 16/00(for the specificity *), and

Indexing Code C07K 2317/14 (source of isolation, production)

Antibody according to its taxonomic origin.

ECLA class C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/20 (general aspects of origin), and/or

Indexing Code C07K 2317/21 (fully primate or fully human, including fully human antibodies produced by transgenic animals, e.g. by Xenomouse®), and/or

Indexing Code C07K 2317/22 (fully camelid), and/or

Indexing Code C07K 2317/23 (fully avian)

Antibody comprising immunoglobulin-regions, -domains or -residues from more than one species, e.g. chimeric, humanized or veneered antibody. Emphasis is on a new technique of construction, not on the antigen specificity.

ECLA class C07K 16/461…. (for the technique), and

ECLA class C07K 16/00 (for the specificity, if in an example *)

Antibody comprising immunoglobulin-regions, -domains or -residues from more than one species, e.g. chimeric, humanized or veneered antibody. Emphasis is on the antigen specificity, not on the technique of construction.

ECLA class C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/24 (chimeric, humanized, veneered antibody)

Antibody characterized by general aspects of specificity or valency.

ECLA class C07K 16/00(for the specificity *), and

Indexing Code C07K 2317/30.

Multispecific (i.e. including bispecific) antibody. Emphasis is on a new technique of construction, not on the antigen specificity.

C07K 16/468 (for the technique of bispecific antibodies), and

C07K 16/00 (for the first specificity, if in an example *), and

C07K 16/00 (for the second specificity, if in an example *), and

optionally C07K 16/00 (for any additional specificity, if in an example *)

Multispecific (i.e. including bispecific) antibody. Emphasis is on the antigen specificity, not on the technique of construction.

C07K 16/00 (for the first specificity *), and

C07K 16/00 (for the second specificity *), and

C07K 16/00 (for any additional specificity, if in an example *), and

Indexing Code C07K 2317/31 (multispecific antibody)

Antibody specific for a neo-epitope formed by a complex, e.g. antibody-antigen, ligand-receptor. The antibody is monospecific, not bispecific !

C07K 16/00 (for the first component of the complex *), and

C07K 16/00(for the second component of the complex *), and

Indexing Code C07K 2317/32 (to indicate specificity for the complex)

Antibody characterized by its crossreactivity (e.g. for species or epitope) or lack of crossreactivity.

C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/33 (for the aspect of crossreactivity or explicit lack thereof).

Antibody characterized by its specificity for a well-defined epitope or immunogen which is either linear and shorter than 20 amino acid residues, or conformational and defined by amino acid residues.

C07K 16/00 (for the specificity for the antigen *), and

Indexing Code C07K 2317/34 (linear epitope <20 AA residues or conformational epitope defined by AA residues)

Antibody characterized by its valency, and wherein the fact that the molecule is monovalent, bivalent or multivalent is an important feature.

ECLA class C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/35 (for the aspect of valency, but only if important).

Antibody characterized by its post-translational modification.

C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/40 (for the aspect of post-translational modification).

Antibody wherein the presence, absence or modification by glycosylation, sialylization, fucosylation is an important feature.

C07K 16/00 (for the specificity *), and

Indexing Code C07K 2317/41 (glycosylation, sialylization, fucosylation)

Antibody characterized by immunoglobulin fragments.The mere provision of an amino acid or nucleotide sequence is not enough to justify one or more of the following codes:

C07K 16/00 (for the specificity of the antigen binding part *), and

Indexing Code C07K 2317/50 (fragments in general), and/or

Indexing Code C07K 2317/51 (complete heavy chain or Fd fragment), and/or

Indexing Code C07K 2317/515 (complete light chain), and/or

Indexing Code C07K 2317/52 (Fc or constant region, isotype), and/or

Indexing Code C07K 2317/522 (CH1), and/or

Indexing Code C07K 2317/524 (CH2), and/or

Indexing Code C07K 2317/526 (CH3), and/or

Indexing Code C07K 2317/528 (CH4), and/or

Indexing Code C07K 2317/53 (hinge), and/or

Indexing Code C07K 2317/54 (F(ab’)2), and/or

Indexing Code C07K 2317/55 (Fab or Fab’), and/or

Indexing Code C07K 2317/56 (variable = Fv), and/or

Indexing Code C07K 2317/565 (CDR), and/or

Indexing Code C07K 2317/567 (framework = FR), and/or

Indexing Code C07K 2317/569 (single domain = sdAb or dAb)

Codes in the C07K 2317/522-C07K 2317/53 series should only be given for features concerning these specific domains; otherwise the C07K 2317/52 code should be given. Said specific domains need not necessarily be in isolated form, but may be in the context of their immunoglobulin molecule or fragments thereof.

If features of both CDRs (or individual residues therein) and FRs (or individual residues therein) are disclosed, both the C07K 2317/565 and C07K 2317/567 codes should be given, and not the general C07K 2317/56 code. The C07K 2317/56 code should be given for general features of the variable region.

Antibody characterized by non-natural combinations of immunoglobulins or fragments.This includes fusion proteins and chemically linked immunoglobulins or their fragments. Excluded are chimeric, humanized or veneered antibodies (see above).

C07K 16/00(for the specificity *), and

Indexing Code-code C07K 2317/60 (general aspects), and/or

Indexing Code C07K 2317/622 (single chain = scFv), and/or

Indexing Code C07K 2317/624 (disulfide stabilized variable = dsFv), and/or

Indexing Code C07K 2317/626 (diabody, triabody), and/or

Indexing Code C07K 2317/64 (comprising a combination of variable region and constant region components), and/or

Indexing Code C07K 2317/66 (comprising a swap of domains, e.g. CH3-CH2, VH-CL, VL-CH1).

optionally Indexing Code C07K 2319/00 (if fusion protein)

Antibody characterized by an effect upon binding to a cell or to an antigen

C07K 16/00(for the specificity *), and

Indexing Code C07K 2317/71 (decreased effector function due to an Fc-modification), and/or

Indexing Code C07K 2317/72 (increased effector function due to an Fc-modification), and/or

Indexing Code C07K 2317/73 (induction of cell death, e.g. apoptosis, necrosis; inhibition of cell proliferation), and/or

Indexing Code C07K 2317/732 (antibody-dependent cellular cytotoxicity (ADCC)), and/or

Indexing Code C07K 2317/734 (complement-dependent cytotoxicity (CDC)), and/or

Indexing Code C07K 2317/74 (induction of cell proliferation), and/or

Indexing Code C07K 2317/75 (agonist effect on antigen), and/or

Indexing Code C07K 2317/76 (antagonist effect on antigen, neutralization, inhibition of binding), and/or

Indexing Code C07K 2317/77 (internalization into the cell).

Antibody characterized by remaining in the (producing) cell, i.e. intracellular antibody = intrabody

C07K 16/00(for the specificity *), and

Indexing Code C07K 2317/80 (general aspects), and/or

Indexing Code C07K 2317/81 (intracellular antibody functional in the ER or Golgi apparatus), and/or

Indexing Code C07K 2317/82 (intracellular antibody functional in the cytoplasm, the nucleus, the mitochondria, the inner part of the cell membrane)

Antibody characterized by(pharmaco)kinetic aspects or stability of the immunoglobulin.

C07K 16/00(for the specificity *), and

Indexing Code C07K 2317/90 (general aspects), or

Indexing Code C07K 2317/92 (for affinity (KD), association rate (Ka), dissociation rate (Kd), EC50 value), or

Indexing Code C07K 2317/94 (in vivo stability, e.g. half-life, pH-, temperature- or enzyme-resistance; Note: for in vitro/pretreatment storage stability see A61K 39/39591).

Antibody mimetics and scaffolds.

C07K 16/00(for the specificity of the inserted antigen binding sequences from antibodies *), and

Indexing Code C07K 2318/00 (general aspects of antibody mimetics and scaffolds)

Immunoglobulin or domain(s) thereof as scaffolds for inserted non-immunoglobulin peptide sequences, e.g. for vaccination purposes, e.g. synthebody.

C07K 14/00(for the non-immunoglobulin protein that is inserted), and

C07K 16/00(for the specificity of the immunoglobulin scaffold *), and

Indexing Code C07K 2318/10 (to indicate the combination of immunoglobulin scaffold molecules with inserted non-immunoglobulin peptide sequences)

Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region, antibody mimetics.

C07K 14/00(for the non-immunoglobulin protein that provides the scaffold).

C07K 16/00(for the antibody-like specificity of the scaffold molecule *).

Indexing Code C07K 2318/20 (for scaffold molecules with antigen binding properties)

The correct specificity of an antibody for a certain antigen (with synonyms) may be found in the regularly updated "keyword/classification index" on the intranet page of the Biotech cluster (under "search", then under "classification", and then under "C07K 16/00").

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Valency
Number of bonds formed between the antigen-binding molecule (e.g. an antibody or fragment thereof) and the target antigen
dAb, sdAb
Single domain antibody
VHH, Nanobody®
Single domain antibody derived from camelids, e.g. camels, llamas, dromedaries, characterized by an extended CDR3 loop.
VNAR
Single domain antibody derived from cartilageous fishes, e.g. sharks, rays
Synonyms and Keywords

In patent documents the following abbreviations are often used:

Ig
Immunoglobulin
Ab
Antibody
mAb, moAb
Monoclonal antibody

version V4 of 28.02.2012

Carrier-bound or immobilised peptides ( carrier-bound or immobilised enzymes C12N 11/00) ; Preparation thereof
Definition statement
This subclass/group covers:

Peptides of any size, i.e. including proteins, that are immobilised or bound to a carrier, and processes for the immobilisation or for the binding of peptides to carriers.

Relationship between large subject matter areas

Immobilised or carrier-bound peptides being part of a functional device, are usually classified according to (the purpose of) the device, e.g. A61M 1/00 for plasmapheresis, B01J 20/00 for affinity chromatography and general sorbent materials.

Immobilized or carrier-bound enzymes or microbial cells

Libraries of peptides

Screening of peptide libraries presented on the surface of microorganisms

Analytical reagents/devices comprising immobilised or carrier-bound peptides, as well as methods involving the same

Use of immobilized peptides as stationary phases in affinity chromatography for the preparation of (other) peptides

Peptides conjugated to carrier moieties in the context of the delivery of therapeutic agents

Peptides conjugated to carrier moieties in the context of the delivery of diagnostic agents

References relevant to classification in this group
This subclass/group does not cover:
  • Immobilised or carrier-bound peptides that are enzymes or are part of microbial cells,
  • - Processes and methods wherein the immobilised or carrier-bound peptides are used;
  • - Processes for the immobilisation or for the binding of peptides to carriers, wherein said processes are specific for a peptide or a certain group of peptides. In these cases, the classification follows the specific peptide(s).
Special rules of classification within this group

Particular attention is given to the nature of the solid support or the carrier and/or to the interaction of the peptide with it.

When the immobilised or carrier-bound peptides is part of a functional device, and no special interaction of the peptide with the solid support or the carrier makes a contributions over the state of the art, no class within C07K 17/00 is assigned.

The last place rule is applicable to each different embodiment disclosed, if more than one is present.

Glossary of terms
In this subclass/group, the following terms (or expressions) are used with the meaning indicated:
Peptides
compounds containing at least two amino acid units, which are bound through at least one normal peptide link, including oligopeptides, polypeptides and proteins.
Amino acids
compounds in which at least one amino group and at least one carboxyl group are bound to the same carbon skeleton and the nitrogen atom of the amino group may form part of a ring.
Normal peptide link
one between an alpha-amino group of an amino acid and the alpha-carboxy group of another alpha-amino acid.
Hybrid peptides
Definition statement
This subclass/group covers:

Hybrid peptides characterised by their non-peptide moiety, e.g. a nucleic acid; non-covaletly bound complexes of two (or more) different peptides.

Relationship between large subject matter areas

Preparations for medical, dental, or toilet purposes are classified in A61K.

References relevant to classification in this group
This subclass/group does not cover:
Fusion proteins, PEGylated proteins
Fusion proteins of an immunoglobulin with a peptide not being an immunoglobulin
General processes for the preparation of hybrid peptides
Genetic engineering processes for obtaining hybrid peptides
Preparation of hybrid peptides and proteins by fermentation or enzyme-using processes
Informative references
Attention is drawn to the following places, which may be of interest for search:
Peptides in foodstuffs
Macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific, but for a random sequence of the amino acid units, homopolyamides and block copolyamids derived from amino acids
Macromolecular products derived from proteins
Preparation of glue or gelatine
Micro-organisms
Compositions for measuring or testing processes involving enzymes
Investigation or analysis of biological material
This page is owned by Office of Patent Classification.
Last Modified: 10/11/2013